Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has commenced a Phase 1 clinical trial for PF-05280602, an investigational drug for FVIIa Hemophilia, developed by Catalyst Biosciences.
Subscribe to our email newsletter
PF-05280602 is an engineered variant of recombinant human Factor VIIa which is said to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors.
Under the terms of their research and license agreement between the two companies, the IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7m payable to Catalyst by Pfizer.
Catalyst CEO Nassim Usman said the company is glad that the lead candidate from Catalyst’s hemostasis franchise advance into human clinical trials.
"In parallel, Catalyst is independently achieving significant progress in engineering next-generation recombinant human Factor IX and Xa variants with highly differentiated advantages for the treatment of acute and prophylactic bleeding disorders, including hemophilia and non-hemophilia indications," Usman added.